Evidence map›Paper›PMID 32821942›Full record

ArticleNucleic acids research2020

PINCER: improved CRISPR/Cas9 screening by efficient cleavage at conserved residues.

Brendan Veeneman, Ying Gao, Joy Grant, David Fruhling, James Ahn, Benedikt Bosbach, Jadwiga Bienkowska, Maximillian Follettie, Kim Arndt, Jeremy Myers and 1 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Comparison of CRISPR-MAD7 and CRISPR-Cas9 for Gene Disruptions inJournal of fungi (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Brendan VeenemanOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Ying GaoOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Joy GrantOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
David FruhlingOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
James AhnOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Benedikt BosbachEmerging Sciences & Innovation, Pfizer Worldwide Research, Development and Medical, New York, NY 10016, USA.
Jadwiga BienkowskaOncology Research and Development, Pfizer Worldwide Research, Development and Medical, San Diego, CA 92121, USA.
Maximillian FollettieOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Kim ArndtOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Jeremy MyersOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.
Wenyan ZhongOncology Research and Development, Pfizer Worldwide Research, Development and Medical, Pearl River, NY 10965, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9 functional genomic screens have emerged as essential tools in drug target discovery. However, the sensitivity of available genome-wide CRISPR libraries is impaired by guides which inefficiently abrogate gene function. While Cas9 cleavage efficiency optimization and essential domain targeting have been developed as independent guide design rationales, no library has yet combined these into a single cohesive strategy to knock out gene function. Here, in a massive reanalysis of CRISPR tiling data using the most comprehensive feature database assembled, we determine which features of guides and their targets best predict activity and how to best combine them into a single guide design algorithm. We present the ProteIN ConsERvation (PINCER) genome-wide CRISPR library, which for the first time combines enzymatic efficiency optimization with conserved length protein region targeting, and also incorporates domains, coding sequence position, U6 termination (TTT), restriction sites, polymorphisms and specificity. Finally, we demonstrate superior performance of the PINCER library compared to alternative genome-wide CRISPR libraries in head-to-head validation. PINCER is available for individual gene knockout and genome-wide screening for both the human and mouse genomes.

Indexed as

AlgorithmsCRISPR-Cas SystemsDatabases, GeneticAmino AcidsAmino Acid SequenceAnimalsCell LineConserved SequenceEnzymesGenomeGenomic LibraryHumansMiceProteinsReproducibility of ResultsRNA, Guide, CRISPR-Cas SystemsAmino AcidsEnzymesProteinsRNA, Guide, CRISPR-Cas SystemsThymidine

Identifiers

PMID32821942
PMCPMC7515706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.